WO2009038701A2 - Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same - Google Patents
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same Download PDFInfo
- Publication number
- WO2009038701A2 WO2009038701A2 PCT/US2008/010778 US2008010778W WO2009038701A2 WO 2009038701 A2 WO2009038701 A2 WO 2009038701A2 US 2008010778 W US2008010778 W US 2008010778W WO 2009038701 A2 WO2009038701 A2 WO 2009038701A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- formulation
- hours
- organic acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 238000009472 formulation Methods 0.000 title claims abstract description 116
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims description 149
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title abstract description 8
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title abstract description 8
- 238000001802 infusion Methods 0.000 claims description 83
- 239000000243 solution Substances 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 150000007524 organic acids Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 34
- 230000005764 inhibitory process Effects 0.000 claims description 30
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 29
- 239000012141 concentrate Substances 0.000 claims description 23
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 17
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000008366 buffered solution Substances 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 201000001441 melanoma Diseases 0.000 claims description 13
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 239000001509 sodium citrate Substances 0.000 claims description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 43
- 238000001990 intravenous administration Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 21
- 238000010348 incorporation Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 108091007914 CDKs Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000011727 Caspases Human genes 0.000 description 11
- 108010076667 Caspases Proteins 0.000 description 11
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 11
- 206010025323 Lymphomas Diseases 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 231100000682 maximum tolerated dose Toxicity 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 9
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 6
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- -1 3-amino-4- substituted pyrazole Chemical class 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006882 induction of apoptosis Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 201000009047 Chordoma Diseases 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 206010047741 Vulval cancer Diseases 0.000 description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000011260 aqueous acid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002628 peritoneum cancer Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 201000005102 vulva cancer Diseases 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102000002554 Cyclin A Human genes 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- PTHDBHDZSMGHKF-SSDOTTSWSA-N 2-[(2r)-piperidin-2-yl]ethanol Chemical group OCC[C@H]1CCCCN1 PTHDBHDZSMGHKF-SSDOTTSWSA-N 0.000 description 1
- DMGGLIWGZFZLIY-UHFFFAOYSA-N 3-methyl-1-oxidopyridin-1-ium Chemical group CC1=CC=C[N+]([O-])=C1 DMGGLIWGZFZLIY-UHFFFAOYSA-N 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000029330 CSK Tyrosine-Protein Kinase Human genes 0.000 description 1
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000007390 esophageal adenoid cystic carcinoma Diseases 0.000 description 1
- 201000010181 esophageal neuroendocrine tumor Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- DBGFNLVRAFYZBI-UHFFFAOYSA-N n-methylpyridin-3-amine Chemical group CNC1=CC=CN=C1 DBGFNLVRAFYZBI-UHFFFAOYSA-N 0.000 description 1
- 230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035921 thrombopoiesis Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- This application discloses a novel formulation containing a 3-amino-4- substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation.
- the mammalian cell cycle is a non-redundant process that integrates extracellular signaling, DNA synthesis, and mitosis.
- Disregulation of cell cycle control is a hallmark of all human cancers and is frequently associated with aberrant activation/regulation of cyclin-dependent kinases, also termed herein for convenience, CDKs.
- CDKs cyclin-dependent kinases
- the lack of cell cycle regulation in tumor cells is believed to increase the propensity of apoptosis in tumor cells compared to normal tissue. Accordingly, specific CDK inhibitors may preferentially kill tumor cells while inducing only reversible cell cycle arrests within normal proliferating compartments. Tumor cell apoptosis may be achievable without mutagenic effect to normal tissue. Therefore, identification of compounds inhibiting essential, rate-limiting activities of CDK2 and CDK1 presents an attractive therapeutic strategy for treatment and management of oncology indications.
- CDK inhibitors Compounds having cyclin-dependent kinase inhibiting properties (CDK inhibitors) and which contain a 3-amino-4-substituted pyrazole derivative structure are described in U.S. Patent No. 7,119,200 to Guzi et al. (herein, "the '200 patent” and herein incorporated by reference in its entirety ), issued October 10, 2006. Efficient syntheses of these CDK-inhibiting compounds, for example, the compounds of Formula I, are described in published U.S. application no. 2006/0281756 (the '756 publication, herein incorporated by reference in its entirety),
- R 1 , R 2 , R 3 , and R 4 are as defined in the 756 publication, which is inco ⁇ orated herein in its entirety by reference.
- the compounds of Formula I are useful in the therapy of proliferative diseases, for example, cancerous tumors.
- the compound of Formula Il may be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, for example breast cancer; colon, for example, colo-rectal cancer, kidney, bile duct, liver, lung, for example, small cell lung cancer and non small • cell lung cancer, esophagus, gall bladder, pancreas, stomach, cervix, thyroid, prostate, ovarian cancer, vulvar cancer, peritoneal cancer, pseudomyxoma peritonei, and skin, for example, melanoma, and squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), B-cell lymphoma T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma [e.g.
- One preferred aspect of the present invention is the provision of a concentrated pharmaceutical formulation containing the compound of Formula II, which can be adapted for administration to a mammal in need of treatment having a tumor responsive to the compound of Formula II, the formulation comprising the compound of Formula II, citric acid, sodium citrate and water at a pH of from about pH 2.5 to about pH 7.0.
- the buffered solution has a pH of from about 3.4 to about 5.
- the formulation comprises an aqueous solution containing on a wt./vol. basis: (a) 5 mg/ml of the compound of Formula II; (b) 21.4 mg/ml citric acid; and (c) 11.4 mg/ml sodium citrate dehydrate optionally admixed with hydrochloric acid and/or sodium hydroxide sufficient to adjust the pH of the concentrate to a pH of from about pH 2.5 to about pH 7.0, preferably the pH is adjusted to a pH of from about pH 3.0 to about pH 4.0, more preferably the pH is adjusted to about pH 3.5.
- Another preferred aspect of the invention is an IV-infusible formulation
- a buffered solution having a pH of from about pH 2.5 to about pH 7.0
- the formulation provides at least one PK behavior at a dosage indicated in accordance with those at shown in Figure 2A and/or 2B and/or in Table V, when infused into a human at the indicated dosage levels.
- the buffered solution has a pH of from about 3.4 to about 5.
- the formulation provides at least one of the AUC/dose curves illustrated in Figures 2A and/or 3 when infused at the dosage level shown for each curve in a 2-hour infusion.
- an IV-infusible formulation comprising the compound of Formula Il in a buffered solution having a pH of from about pH 2.5 to about pH 7.0, the formulation provides at least one PK behavior at a dosage indicated in accordance with those at shown in Figure 2C and/or Table Vl, when infused into a human at the indicated dosage levels.
- the formulation provides at least one of the AUC/dose curves illustrated in Figure 2C when infused at the dosage level shown for each curve in a 2-hour infusion.
- the buffered solution has a pH of from about 3.4 to about 5.
- Another preferred aspect of the invention is the provision of a formulation comprising an aqueous organic acid, its conjugate salt, and the compound of Formula Il which provides the PK profile shown in Figure 2A, 2B, and/or 2C upon IV infusion into a human.
- the formula comprises a mole ratio of the compound of Formula Il : organic acid : conjugate salt of: 1 mole of the compound : 8.8 moles of organic acid : 3.7 moles of conjugate salt.
- the formulation provides a PK for a two hour infusion of a dose comprising 1.85 mg/M 2 having a U /2 of about 2.15 hours, a Cmax of about 77 ng/ml, and/or an AUC of about 181 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 3.7 mg/M 2 having a t 1/2 of about 2.75 hours, a C max of about 136 ng/ml, and/or an AUC of about 336 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 7.4 mg/M 2 having a ti /2 of about 2.86 hours, a C max of about 353 ng/ml, and/or an AUC of about 994 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 14.8 mg/M 2 having a ti /2 of about 2.78 hours, a C max of about 396 ng/ml, and/or an AUC of about 1053 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 29.6 mg/M 2 having a t 1/2 of about 2.79 hours, a C max of about 1020 ng/ml, and/or an AUC of about 2531 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 41.4 mg/M 2 having a ti /2 of about 2.8 hours, a C max of about 1343 ng/ml, and/or an AUC of about 3041 ng hr/mL. More preferably the formulation provides a PK for a two hour infusion of a dose comprising 50 mg/M 2 having a t- ⁇ /2 of about 2.9 hours, a C max of about 1820 ng/ml, and/or an AUC of about 4050 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 58 mg/M 2 having a ti /2 of about 3.2 hours, a C max of about 1460 ng/ml, and/or an AUC of about 3290 ng hr/mL.
- Table VIII is a cumulative representation of the data in Tables V, Vl and VII with an expansion in patient numbers at certain doses as indicated in Table VIII.
- Another embodiment is the provsion of a formulation comprising an aqueous organic acid, its conjugate salt, and the compound of Formula Il which provides the PK profile shown in Figure 2A, 2B, and/or 2C upon IV infusion into a human.
- the formula comprises a mole ratio of the compound of Formula Il : organic acid : conjugate salt of: 1 mole of the compound : 8.8 molesof organic acid : 3.7 moles of conjugate salt..
- the formulation provides a PK for a two hour infusion of a dose comprising 1.85 mg/M 2 having a Ui 2 of about 2,29 hours, a C max of about 91 ng/ml, and/or an AUC of about 211 ng hr/mL
- the formulation provides a PK for a two hour infusion of a dose comprising 3.7 mg/M 2 having a ti /2 of about 2.75 hours, a C max of about 136 ng/ml, and/or an AUC of about 336 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 7.4 mg/M 2 having a t 1/2 of about 2.86 hours, a C max of about 353 ng/ml, and/or an AUC of about 972 ng hr/mL.
- the formulation provides a PK for a two-hour infusion of a dose comprising 14.8 mg/M 2 having a tv 2 of about 2.78 hours, a C max of about 396 ng/ml, and/or an AUC of about 1050 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 29.6 mg/M 2 having a ti /2 of about 2.98 hours, a C ma ⁇ of about 890 ng/ml, and/or an AUC of about 2430 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 41.4 mg/M 2 having a ti /2 of about 2.8 hours, a C max of about 1300 ng/ml, and/or an AUC of about 2890 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 50 mg/M 2 having a ti ⁇ of about 2.9 hours, a C max of about 1820 ng/ml, and/or an AUC of about 4090 ng hr/mL.
- the formulation provides a PK for a two hour infusion of a dose comprising 58 mg/M 2 having a tv 2 of about 3.2 hours, a C max of about 1460 ng/ml, and/or an AUC of about 3300 ng hr/mL.
- the concentrate by providing a solution containing an organic acid and its conjugate salt, dissolve the desired amount of the compound of Formula Il therein, titrate the resulting solution with aqueous acid and aqueous base until the solution containing the compound of Formula Il attains the desired pH, and optionally diluting the buffered solution with water or an aqueous solution, for example, a saline solution, to achieve the desired concentration of the compound of Formula II.
- the buffered solution has a pH of from about 3 to about 5.
- it is preferred to prepare the solution used to prepare the concentrate from an organic acid and conjugate salt selected from citric acid/sodium citrate and lactic acid/sodium lactate.
- the present invention comprises treating or managing a disease state by administering the concentrate, or a diluted form of the concentrate, to a mammal in need thereof, preferably by admixing the concentrate with the contents of a Normal Saline USP IV bag, preferably a standard 250 ml saline IV bag, to provide a medicament suitable for intraveneous infusion.
- a Normal Saline USP IV bag preferably a standard 250 ml saline IV bag
- an amount of the diluted concentrate is administered to a mammal in need of treatment equal to from about 0.33 mg/m 2 to about 58 mg/m 2 of the compound of Formula II, preferably from about 0.33 mg/m 2 to about 58 mg/m 2 of the compound of Formula II, more preferably from about 50 mg/m 2 to about 58 mg/m 2 of the compound of Formula II. In some embodiments it is preferred to administer about 50 mg/m 2 of the compound of Formula II. In some embodiments it is preferred to administer the diluted concentrate by IV infusion.
- the amount of diluted concentrate necessary to provide the desired amount of the compound of Formula Il over a period of from about 1 hour to about 24 hours.
- administering an IV infusion comprising a dose of from about 0.33 mg/m 2 of the compound of Formula Il to about 58 mg/m 2 of the compound of Formula Il it is preferred to administer the infusion over a period of about 2 hours.
- administering to a mammal in need of therapy an amount of diluted concentrate necessary to provide a dose of 14.8 mg/m 2 of the compound of Formula Il at an infusion rate that yields a steady state plasma concentration of about
- compound of Formula Il is administered in one or more cycles at the desired dose density.
- the compound of Formula Il i ⁇ administered in a 28-day cycle comprising once weekly administration of the compound of Formula Il for three weeks with one week off.
- the compound of Formula Il is administered in a 21 -day cycle comprising administration at Day 1 followed by 20 days off.
- Figure 1 presents a graph estimating the concentration(ng/ml) versus time(hours) profile for a 24 hour infusion of a solution comprising 14.8 mg/m 2 of the compound of Formula II.
- Figure 2A presents a graph showing C max and mean concentration/time profiles in volunteer human patients receiving one of 9 different 2-hour IV infusion - administered doses of the present formulation in an amount ranging from 0.33 mg/m 2 to 41.4.6 mg/m 2 of the compound of Formula Il over a 12 hour time period.
- Figure 2B presents a graph showing mean concentration/time profiles in volunteer human patients receiving one of 9 different 2-hour IV infusion -administered - doses of the present formulation ranging from 0.33 mg/m 2 to 41.4 mg/m 2 of the . compound of Formula Il over a 24 hour time period.
- Figure 2C presents a graph showing mean concentration/time profiles in volunteer human patients receiving one of 8 different 2-hour IV infusion -administered doses of the present formulation in an amount ranging from 1.85 mg/m 2 to 58 mg/m 2 of the compound of Formula Il over a 12 hour time period.
- Figure 3 presents a graph showing exposure in healthy human volunteers for a series of doses of the present formulation containing an amount of the compound of Formula Il ranging from 0.33 mg/m 2 to 41.4 mg/m 2 administered by 2 hour infusion IV.
- Figure 4 presents a graph showing the effects of various dosing regimes of the compound of Formula Il on tumor volume suppression in A549 NSCLC mouse xenograft models.
- Figure 5 presents a graph showing the binding affinity of the compound of Formula Il to Cyclin A/CDK2 complexes.
- Figure 6 presents a graph showing the inhibition effect of the compound of Formula Il in A2780 mouse xenograft ovarian cancer model.
- Figure 7 presents micrographs of typical hair follicles harvested from nude mice exposed to dosages of the compound of Formula II, demonstrating suppression of phospho-Rb within the proliferating epithelial cells of the basal epithelium and hair follicles.
- Figure 8 presents a graph showing concentration/time profiles for a patient administered by 2 hour IV infusion a dose of the compound of Formula Il in the amount of 1.85 mg/m 2 as observed on days 1 and 15 of a 28 day dosing cycle.
- Figures 9A and 9B present individual patient PK profiles over 24 hours after receiving IV infusion dosages of the compound of Formula Il in the amounts of 29.8 mg/m 2 and 41.4 mg/m 2 respectively.
- Figure 10 presents data showing the effect of various dosage levels of the compound of Formula Il on BrdU incorporation in ex vivo blood samples.
- Figure 11 presents a chart showing falling levels of biomarkers in a patient diagnosed with pseudomyxoma peritonei after receiving 6 cycles of IV infusion dosages of the compound of Formula II.
- Figures 12A and 12B present data showing the effect of various dosage levels of the compound of Formula Il on BrdU incorporation in ex vivo blood samples.
- Figure 13 presents data showing the percentage inhibition of BrdU incorporation at an 8 hour timepoint following exposure to various dosage levels of the compound of Formula Il in ex vivo blood samples.
- compounds of Formula Il have activity as useful pharmaceutical compounds having cyclin-dependent kinase inhibiting properties.
- the inventors have surprisingly found that the compound of Formula II, when administered as an IV formulation is provided in therapeutic levels.
- the compound of Formula Il inhibits the cyclin-dependent kinases CDK1 with a calculated drug affinity (IC 50 ) of 4 nM, CDK2 with calculated drug affinity (IC 50 ) of 1 nM, CDK5 with a calculated drug affinity (IC 50 ) of 1 nM, and CDK9 with a calculated drug affinity (IC 50 ) of 4nM.
- the inventors have surprisingly found inhibition of CDK2/CDK1 in tumor cells leading to cell cycle arrest and apoptosis in more than 100 tumor cell lines including the standard NCI panel. Additionally, the inventors have surprisingly found that exposure of xenograft models to plasma trough concentrations of less than 25 nM of the compound of Formula Il for less than two hours results in tumor growth inhibition or regression.
- a formulation containing the compound of Formula Il suitable for IV administration to humans to achieve beneficial plasma levels for the treatment or ; management of proliferative disorders can be prepared which formulation comprises a buffered aqueous solution of the compound of Formula II.
- the formulations comprising the compound of Formula II, methods of treating benign and proliferative disease states using the formulations of the invention containing the compound of Formula II, and examples are described next in greater detail.
- an IV Formulation Comprising the Compound of Formula Il One aspect of the present invention is a formulation comprising the compound of Formula Il suitable for intravenous (IV) administration.
- the compound of Formula Il is soluble in acidic media, but sparingly soluble in neutral and basic media.
- a suitable formulation can be prepared by dissolving the compound of Formula Il in an acidic solution made by dissolving in water an organic acid suitable for incorporation into a buffered system, and then titrating the solution of the compound of Formula Il and dissolved organic acid to a desired final pH using a suitable base and a suitable acid as necessary to adjust the pH.
- Suitable acids are any organic that can provide an aqueous solution having a pH more acidic than about pH 7.0, preferably a pH at least as acidic as pH 3.5, and when titrated with a suitable base can provide a buffer solution having a pH in the range which includes from about pH 7 to about pH 2.5, and preferably can provide a buffer solution having a pH of about pH 3.5.
- the organic acid selected is freely water soluble, for example, lactic or citric acid, more preferable, the organic acid chosen has more than one acidic proton, for example, citric acid.
- the compound of Formula II sparingly soluble in neutral water, is readily soluble in aqueous acid solutions. Accordingly, in some embodiments, in the preparation of the formulation of the invention it is preferred to initially prepare an aqueous acid solution, preferably an acid solution comprising at least about 0.111 M of the selected acid, dissolve therein a conjugate salt, for example, sodium citrate and sodium lactate, and then dissolve in the resulting buffer solution an aliquot of the compound of Formula II. After dissolution is complete the resulting solution is titrated to achieve the desired pH using an acid, for example hydrochloric acid, and base, for example, sodium hydroxide, in the amounts needed to bring the solution to the desired pH or within the desired pH range.
- an acid for example hydrochloric acid
- base for example, sodium hydroxide
- the solution is more basic than about pH 2.5, more preferred is a solution having a pH of from about pH 3 to about pH 5.
- the solution has a pH from about pH 3.0 to about pH 4.2, more preferably from about pH 3.4 to about pH 3.6.
- the formulation of the invention may be prepared using other processes yielding a buffered acidic aqueous solution having the desired concentration of API and a pH of from about pH 2.5 to about pH 7.0, preferably from about pH 3 to about pH 5, more preferably from about pH 3.0 to about pH 4.2, without departing from the formulation of the invention.
- the formulation of the invention is a concentrated formulation intended to be diluted as needed by addition of the concentrate into a standard IV bag containing 250 ml of 0.9% saline solution in an amount that provides the desired number of milligrams of API to effect treatment. It is within the scope of the invention to adjust the concentration of the formulation as necessary to provide a formulation sufficiently concentrated in API to accommodate in the dead space of a 250 ml_ saline bag an amount of the concentrate providing the desired number of mg of API.
- the concentrate contains about 5 mg/ml and when needed in an amount in excess of that which can be accommodated within the dead space of a 250 ml saline bag, the amount of concentrate needed is divided into aliquots which are added to multiple saline bags for administration to the patient.
- the pH will be altered.
- the pH of the infusible solution is between pH 3.4 and pH 7, more preferably between about pH 3.4 and about pH 5. Slightly more acidic solutions may be obtained at high dilution levels of the concentrate, as will be appreciated, due to the lowered buffering ability of the concentrate with increasing dilution. It will be appreciated that any pH value compatible with the patient's physiology can be used as long as infusion time is adjusted to prevent or minimize damage to the vein in which the composition is infused.
- the formulation of the invention is an aliquot of a sufficient amount of the above-described concentrate diluted in an amount of a saline solution to provide an IV infusible solution containing a sufficient amount of the compound of Formula Il to provide a therapeutic level of the compound of Formula Il to a patient when infused into the patient.
- typically up to about 58 mg/m 2 of the compound of Formula Il is administered to a patient in need of therapy, although greater amounts and lesser amounts can be administered as desired.
- about 50 mg/m 2 to about 58 mg/m 2 of the compound of Formula Il is administered to a patient in need of therapy.
- about 50 mg/m 2 is administered to a patient in need of therapy.
- the entire amount of concentrate diluted in saline solution is infused to a patient over a period of time, typically a period of from about 2 hours to about 24 hours. In some embodiments it is preferred to infuse the entire amount of the formulation to a patient over a 2 hour period.
- this dosage density in a 21 -day cycle that is, as a single 50 mg/m 2 dose every 3 weeks ⁇ i.e., administration at Day 1 followed by 20 days off). In other embodiments, it is preferred to administer a dosage density of about 58 mg/m 2 / 3 weeks. In some embodiments, it is preferred to administer this dosage density in a 28-day cycle, that is, as a 19.3 mg/m 2 dose once-a-week for 3 weeks followed by one week off. In some embodiments, it is preferred to administer this dosage density in a 21-day cycle, that is, as a single 58 mg/m 2 dose every 3 weeks ⁇ i.e., administration at Day 1 followed by 20 days off). Greater or lesser amounts can be used.
- Administration cycles which provide regular doses for example, a 28-day cycle comprising once weekly administration for three weeks with a week off, or a 21 -day cycle comprising administration at Day 1 followed by 20 days off, can be employed to provide the desired dose density.
- the novel formulation(s) containing a CDK inhibitor of Formula Il are believed to act as reversible cytostatic agents useful in the treatment of any disease process which features abnormal cellular proliferation, for example tumor growth, for example, in treating cancer, including solid tumors such as skin, for example, melanoma, breast, for example breast cancer, brain, colon and colorectal cancer, prostate cancer, for example, prostate cancer, gall bladder, thyroid, cervical carcinomas, testicular carcinomas, vulvar cancer, pseudomyxoma peritonei, peritoneal cancer, ovarian cancer, non small cell lung cancer (NSCLC), etc.
- NSCLC non small cell lung cancer
- cancers that may be treated by the compounds, compositions and methods of the invention include, but are not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancre
- a formulation of the invention comprising a CDK inhibitor of Formula Il is used to treat non-small cell lung cancer (NSCLC), breast cancer, ovarian cancer, acute leukemias [e.g., acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL)], chronic leukemias (e.g., CLL), non-Hodgkin's lymphoma (e.g., MCL), melanoma, and multiple myeloma.
- NSCLC non-small cell lung cancer
- AML acute myelogenous leukemia
- ALL acute lymphocytic leukemia
- CLL chronic leukemias
- non-Hodgkin's lymphoma e.g., MCL
- melanoma melanoma
- a formulation of the invention comprising a CDK inhibitor of Formula Il is administered to a patient over an 8 hour period.
- dosage ranges of a formulation of the invention comprising a CDK inhibitor of Formula Il for an 8 hour infusion period may be from about 1.85 mg/m 2 to about 70 mg/m 2 and from about 15 mg/m 2 to about 30 mg/m 2 . In some embodiments this dosage is administered as a 21 day cycle (administration on Day 1 followed by 20 days off).
- a formulation of the invention comprising a CDK inhibitor of Formula Il is administered to a patient over a 24 hour period.
- dosages ranges for a 24 hour period may be from about 1.85 mg/m 2 to about 100 mg/m 2 , from about 50 mg/m 2 to about 80 mg/m 2 and from about 30 mg/m 2 to about 70.0 mg/m 2 .
- this dosage is administered as a 21 day cycle (administration on Day 1 followed by 20 days off)-
- solid tumors e.g., breast, melanoma, ovarian
- solid tumors are treated by the methods described herein.
- a dosage of a formulation comprising a CDK inhibitor of formula Il from about 1.85 mg/m 2 to about 58 mg/m 2 is administered on a 21 day cycle (i.e., administration at Day 1 followed by 20 days off).
- the dosage may be infused over a 2 hour, 8 hour or 24 hour time period.
- solid tumors e.g., breast, melanoma, ovarian
- growth factors e.g. GCSF and GMCSF
- dosage ranges of a formulation of the invention comprising a CDK inhibitor of Formula Il may be from about 0.33 mg/m 2 and from about 100 mg/m 2 in a 21 day schedule (administration on Day 1 followed by 20 days off). The dosage may be infused over a 2 hour, 8 hour or 24 hour time period.
- CDK inhibitor of Formula Il from about 1.85 mg/m 2 to about 100 mg/m 2 and from about 40 mg/m 2 to about 70 mg/m 2 is administered in a 21 day cycle (i.e., administration at Day 1 followed by 20 days off). The dosage may be infused over a 2 hour, 8 hour or 24 hour time period.
- a dosage of a formulation of the invention comprising a CDK inhibitor of Formula Il from about 0.33 mg/m 2 to about 30 mg/m 2 , from about 0.33. mg/m 2 to about 14 mg/m 2 or from about 7 mg/m 2 to about 12 mg/m 2 is administered in a 28 day cycle (i.e., dosage once a week for three weeks followed by one week off). The dosage may be infused over a 2 hour, 8 hour or 24 hour time period.
- hematologic cancers are treated.
- solid tumors are treated.
- treatment of cancer includes treatment of cancerous cells, including cells afflicted by any one of the above-identified conditions.
- the formulations of the present invention may also be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
- the formulations of the present invention may also be useful in inhibiting tumor angiogenesis and metastasis.
- Example 2 Studies of Xenograft Cancer Model Tumors in Nude Mice The efficacy of the formulation comprising the compound of Formula Il prepared in Example 1 was examined in the A2780 xenograft ovarian cancer model. For all experimental models, maximum tolerated dose was defined as that dose, over the duration of the given schedule, which resulted in a 20% weight loss in subject mice. - In carrying out this study, A2780 cells were inoculated into nude mice subcutaneously and tumors were permitted to grow until they had a volume of approximately 100 mm 3 (approximately 7 days).
- Example II Groups of ten of these test animals were injected IP with the formulation prepared in Example I at dosage levels of: 8 mg/kg (13% maximum tolerated dose (MTD)); 16 mg/kg (27% MTD); 32 mg/kg (53% MTD); and 48 mg/kg (80% MTD), daily for 10 days.
- a solution of paclitaxel was injected IP into a control group at a dosage level of 20 mg/kg twice weekly (50% MTD) along with control groups injected with formulation that did not include API.
- the results of inhibition of tumor growth are shown in Figure 6.
- Figure 6 shows that the control groups had tumor growth to a volume of about 800 mm 3 over the ten day period, while animals that were dosed with paclitaxel had tumor growth inhibited by 63%..
- mice receiving formulation comprising the compound of Formula Il exhibited tumor growth inhibition of 70% (both 8 mg/kg and 16 mg/kg dosing levels), 90% (32 mg/kg dosing level), and 96% (48 mg/kg dosing level). These data show that the 50% inhibition level (which in this model defines the minimum effective dose) is apparently less than 8 mg/kg. Moreover, it was found that animals exposed to the maximum dosage level of the compound of Formula Il showed body-weight loss over the course of the experiment of about 5%, demonstrating that the formulation is well tolerated.
- the formulation was administered to BALB/c mice at a dosage level of 40 mg/kg once per day for five days.
- Blood samples were obtained on days 1 and 7 following the last dose and analyzed on an Advia 120 hematology analyzer immediately after diluting 1 :5 in PBS.
- a full differential blood count was performed, including red blood cell analysis (including reticulocyte, variant count, and hemoglobin analyses), white blood cell analysis (including differential lineage counts and peroxidase staining) and a thrombopoiesis analysis. No effect was observed on platelets or red blood cells.
- nude mice bearing A549 NSCLC xenografts, ⁇ established at a volume of greater than 100 mm 3 were injected with a dosage equivalent to 260 mg/kg of the compound of Formula Il using the formulation prepared in Example I over 5 different schedules shown: (a) 20 mg/kg once a day for 13 days; (b) 29 mg/kg for 3 days, followed by 2 days off for three cycles; (c) 52 mg/kg on days 1 , 4, 7, 10, and 13; (d) 17 mg/kg thrice per day (equivalent to 52 mg/kg in 24 hours) on days 1 , 4, 7, 10, and 13; and (e) 87 mg/kg on days 1 , 7, and 13.
- Nude mice were given a single dose intraperitoneal of the formulation prepared in Example I equivalent to 40 mg/kg. Skin samples were harvested at various intervals following dosing and compared with biopsies harvested prior to dosing (TO). Biopsied samples were fixed overnight in 10% formalin. Samples were then placed in 70% alcohol for storage before being embedded in paraffin blocks, sectioned and stained with phospho-Rb Ser 807/811 -specific antisera.
- the samples taken post- administration of the formulation indicate that the formulation induced rapid and sustained suppression of phospho-Rb within the proliferating epithelial cells of the basal epithelium and hair follicles.
- nude mice bearing xenografts were also dosed at the rate of 87 mg/kg once every six days, with the dosing schedule divided for single daily dose (20 mg/kg), single daily dose for 3 days followed by a 2 day off period (29 mg/kg single dose), single dose every three days (52 mg/kg, single dose), three 17 mg/kg doses in one day, repeated every three days, and one 87 mg/kg dose given every 6 days.
- Tumor regression was observed in animals treated with the compound of Formula Il as compared with a control. The degree of tumor regression was similar for all dosing schedules examined.
- Example 3 Inhibition of Thymidine Incorporation or Alamar Blue Viability in a Variety of Human Tumor Cell Lines and Confirmation of Cell Apoptosis Following Short Exposure to the Compound of Formula Il
- the cells were evaluated fluorometrically for levels of activated caspase six hours post washout. Samples of each cell line were also subjected to SDS-PAGE and subsequently immunoblotted for p85 PARP caspase cleavage product. A positive apoptosis result was deemed if detectable activation of caspases and accumulation of p85 PARP was observed following a two hour exposure of a cell line to less than 0.1 micromolar concentrations of the compound of Formula II.
- Activation of apoptosis following short exposure times of A2780 cells to the compound of Formula Il was confirmed by exposing A2780 ovarian cancer cell cultures to increasing concentrations of the compound of Formula Il dissolved in growth medium for a period of two hours then removing the cells and re-feeding them in complete media without the compound of Formula Il present for six hours (washout period). After the 6 hour washout period, cell extracts were prepared and evaluated by fluorometric assay for activated caspases (RFLU). In this study it was observed that caspase activity was reproducibly detected following 2 hours of exposure to the compound of Formula Il present in as little as 0.05 micromolar concentration. When compared to cells treated with higher concentrations of the compound of Formula Il (up to 5.0 micromolar) it was found that caspase activity did not increase. These data indicate that caspase activity is maximal at exposure levels of 0.05 micromolar.
- asynchronously growing A2780 cells were exposed to concentrations of the compound of Formula Il dissolved in growth media for two hours ranging from 0.001 micromolar to 30 micromolar in 16 batches, each approximately doubling the concentration of the compound of Formula Il over the previous batch concentration.
- the cells were washed out and re- fed growth media without the compound of Formula Il present for 24 hours, then pulsed for 30 minutes with BrdU to establish the percentage of cells undergoing active DNA replication. Cells were then fixed, stained with an FITC-conjugated, anti-BrdU - monoclonal antibody and propidium iodide.
- the cells thus prepared were analyzed using 2-color flow cytometry with doublet-discrimination. This study showed that at exposures of greater than 0.5 micromolar, the compound of Formula Il completely suppressed DNA synthesis 24 hours after exposure. The samples exposed to concentrations of greater than 0.5 micromolar also showed accumulation of subG1 (associated with apoptotic cells). Escalation of exposure above 0.5 micromolar, up to concentrations of 30 micromolar did not augment the apoptotic phenotype.
- Asynchronously growing A2780 cells were exposed to increasing concentrations of the compound of Formula Il or the compound of Formula III for 16 hours.
- Cell lysates were separated on SDS-Page and immunoblotted with a rabbit polyclonal antisera specific for a CDK phosphorylation site (Ser 07/811 ) on the retinoblastoma tumor-suppressor protein (RB, a known CDK substrate).
- Ser 07/811 a rabbit polyclonal antisera specific for a CDK phosphorylation site on the retinoblastoma tumor-suppressor protein (RB, a known CDK substrate).
- RB retinoblastoma tumor-suppressor protein
- the formulation comprising the compound of Formula Il suppressed phospho-Ser 807/811 following exposure.
- Phospho-Ser 807/811 was undetectable in lysates exposed to concentrations of greater than 6.25 nM in the compound of Formula II, and it was observed that complete suppression of detectable RB phosphorylation was required for the onset of apoptosis, indicated by the detectable p85 PARP.
- Table IV indicates that the compound of Formula Il is selective for the CDK family of Ser/Thr kinases, as determined by Upstate kinase Profiler counter-screening, whereas the compound of Formula III has more general activity, including the inhibition of c-Src tyrosine kinase.
- Figure 5 also shows that the compound of Formula Il binds with high affinity to cyclin A/CDK2 complexes.
- Example 1 The formulation prepared in Example 1 was infused into volunteer human cancer patients after diluting it in a 250 ml standard 0.9 % saline IV bag. The contents of the IV bag were infused over a two hour period. Dosages were prepared using an amount of the formulation providing doses of 0.33 mg/m 2 , 0.66 mg/m 2 , 1.32 mg/m 2 , 1.85 mg/m 2 , 2.59 mg/m 2 , 3.63 mg/m 2 ' , 5.08 mg/m 2 , 7.11 mg/m 2 , 10.00 mg/m 2 , 12.00 mg/m 2 and 14.00 mg/m 2 of the compound of Formula Il for the patient infused.
- Each patient was dosed on a 28 day cycle, comprising an infusion once a week for the first three weeks of the cycle on days 1 , 8, and 15 of each cycle, with no dose administered in the week following the third dose.
- Plasma samples were collected prior to the start of an infusion, and at hours 1 , 2 (completion of infusion), 2.25, 2.5, 3.0, 3.5, 4.0, 5.4, 6.0, 8.0, and 24 after the beginning of the infusion.
- Volunteer human cancer patients were also dosed once every three weeks (i.e., on a 21 -day cycle) via a 2 hour IV infusion with 1.85 mg/m 2 , 3.7 mg/m 2 , 7.4 mg/m 2 , 14.8 mg/m 2 , 29.6 mg/m 2 , 41.4 mg/m 2 , 50 mg/m 2 , and 58 mg/m 2 .
- PK and AUC results obtained .- were similar between the 21 -day dosing schedule and the comparable 28-day dosing schedule described above.
- PK parameters observed in these studies are summarized in Table V, Table Vl, and Table VJI. Specifically, the data shown graphically in Figures 2A and 2B correspond to Table V and the data shown graphically in Figure 2C correspond to Tables Vl and VII. These data indicated that PK exhibited moderate inter-subject variability (C max and AUC) and relatively low to moderate intra-subject variability (approximately 30%) at dosages of from about 0.33 mg/m 2 to about 58 mg/m 2 . Observed ti « was between about 1.4 hours and about 3.3 hours.
- Table VIII is a cumulative representation of the data in Tables V, Vl and VII with an expansion in patient numbers at certain doses as indicated in Table VIII.
- AUC(I) area under the plasma concentration-time curve from time zero to infinity
- Blood samples were collected at 2, 3, 4, 6, and 8 hours post initiation of infusion from patients infused (2 hrs) with dosage levels of the compound of Formula Il in amounts equal to 0.33 mg/m 2 ; 0.66 mg/m 2 ; and 1.85 mg/m 2 .
- the samples were collected in tubes containing heparin and shipped to a central laboratory for evaluation.
- Whole blood from each sample was diluted 1 :5 in complete RPMI media and 200 microliter aliquots were added to wells of a 96-well plate. Samples from each time point were either stimulated with PHA (0.01 mg/ml final concentration), or not stimulated.
- the sample well plates were incubated for 48 hours at 37 0 C under 5% CO 2 and BrdU (10 micromolar) was added to each well.
- NSCLC non small cell lung cancer
- colorectal cancer prostate cancer, ovarian cancer, breast cancer, melanoma, vulvar cancer, pseudomyxoma peritonei, peritoneal cancer, cholangiocarcinoma, pancreatic cancer, soft tissue sarcoma, gastric cancer, gastrointestinal stromal tumor (GIST), esophageal cancer, adenoidcystic carcinoma, neuroendocrine tumor or hepatocellular carcinoma
- GIST gastrointestinal stromal tumor
- esophageal cancer adenoidcystic carcinoma
- neuroendocrine tumor or hepatocellular carcinoma have been administered various dosages of the compound of Formula Il by 2 hour IV infusion on a 28-day dosing cycle.
- Each 28-day dosing cycle comprising once weekly administration for three weeks with a week off.
- One patient with melanoma was treated at 3.63 mg/m2 for 9 cycles until disease progression.
- One patient with soft tissue sarcoma receiving 6 cycles at 7.11 mg/m2 continues to have stable disease as does one patient with GIST receiving 5 cycles at 7.11 mg/m2.
- One patient with esophageal cancer receiving 5 cycles at 7.11 mg/m2 has stable disease.
- One patient with adenoidcystic carcinoma received 5 cycles at 7.11mg/m2 until disease progression.
- patients having a diagnosis of a carcinoid, thymic cancer, leiomysarcoma, NSCLC, colorectal cancer, squamous cell carcinoma of the head and neck (HNSCC), adenocarcinoma of unknown primary, melanoma, ovarian cancer, non-Hodgkin's lymphoma, neuroendocrine tumor, testicular cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, thyroid cancer, liposarcoma, cholangiocarcinoma, pseudomyxoma peritonei, chordoma, or sarcomatoid carcinoma were administered various dosages of the compound of Formula Il by 2 hour IV infusion on a 21 -day dosing cycle.
- Patients having a diagnosis of liposarcoma, colorectal cancer, neuroendocrine tumor, NSCLC, and esophageal cancer were administered various dosages of the compound of Formula Il by 8 hour IV infusion on a 21 -day dosing cycle.
- Each 21 -day dosing cycle comprising administration of the dose on Day 1 of a 21 -day period
- stable disease was achieved in some of the aforementioned tumor types after 4 or more 21 -day dosing cycles.
- two carcinoid patients achieved a stable disease state for 4 cycles at a dose of 29.6 mg/m 2 and 41.4 mg/m 2 .
- a thymic cancer patient achieved a stable disease state for 4 cycles at a dose of 50 mg/m 2 .
- a patient with anal cancer achieved stable disease for 6 cycles at a dose of 50 mg/m2.
- a leiomysarcoma patient achieved a stable disease state for 8 cycles at a dose of 41.4 mg/m 2
- a NSCLC patient achieved a stable disease state for 12 cycles at a dose of 50 mg/m 2 .
- a chordoma patient achieved stable disease for 8 cycles at a dose of 58 mg/m2 and a prostate cancer patient achieved stable disease for 7 cycles at a dose of 50 mg/m2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010002927A MX2010002927A (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same. |
NZ584037A NZ584037A (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
BRPI0816823A BRPI0816823A8 (en) | 2007-09-17 | 2008-09-16 | FORMULATION CONTAINING CYCLIN-DEPENDENT KINASE INHIBITOR COMPOUND AND TUMOR TREATMENT METHOD USING IT |
CN200880116604A CN101854915A (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
EP08831837A EP2200584A2 (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
AU2008301925A AU2008301925A1 (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
US12/678,320 US20100286038A1 (en) | 2007-09-21 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
CA2699761A CA2699761A1 (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
JP2010524891A JP2010539173A (en) | 2007-09-17 | 2008-09-16 | Formulations containing cyclin-dependent kinase inhibitor compounds and methods of treating tumors using this formulation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99418507P | 2007-09-17 | 2007-09-17 | |
US60/994,185 | 2007-09-17 | ||
US99946907P | 2007-10-17 | 2007-10-17 | |
US60/999,469 | 2007-10-17 | ||
US5378408P | 2008-05-16 | 2008-05-16 | |
US61/053,784 | 2008-05-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009038701A2 true WO2009038701A2 (en) | 2009-03-26 |
WO2009038701A3 WO2009038701A3 (en) | 2009-09-11 |
Family
ID=40020243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/010778 WO2009038701A2 (en) | 2007-09-17 | 2008-09-16 | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2200584A2 (en) |
JP (1) | JP2010539173A (en) |
KR (1) | KR20100072253A (en) |
CN (1) | CN101854915A (en) |
AU (1) | AU2008301925A1 (en) |
BR (1) | BRPI0816823A8 (en) |
CA (1) | CA2699761A1 (en) |
CO (1) | CO6270205A2 (en) |
MX (1) | MX2010002927A (en) |
NZ (1) | NZ584037A (en) |
SG (1) | SG184760A1 (en) |
WO (1) | WO2009038701A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541587A (en) * | 2010-11-05 | 2013-11-14 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Administration of NEDD8 activating enzyme inhibitor |
WO2015026634A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI632921B (en) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | Solution for oral administration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209878A1 (en) * | 2002-09-04 | 2004-10-21 | Schering Corporation And Pharmacopeia, Inc. | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20080050384A1 (en) * | 2002-09-04 | 2008-02-28 | Shering Corporation And Pharmacopeia, Inc. | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
-
2008
- 2008-09-16 SG SG2012068458A patent/SG184760A1/en unknown
- 2008-09-16 CN CN200880116604A patent/CN101854915A/en active Pending
- 2008-09-16 WO PCT/US2008/010778 patent/WO2009038701A2/en active Application Filing
- 2008-09-16 CA CA2699761A patent/CA2699761A1/en not_active Abandoned
- 2008-09-16 EP EP08831837A patent/EP2200584A2/en not_active Withdrawn
- 2008-09-16 AU AU2008301925A patent/AU2008301925A1/en not_active Abandoned
- 2008-09-16 KR KR1020107008144A patent/KR20100072253A/en not_active Application Discontinuation
- 2008-09-16 BR BRPI0816823A patent/BRPI0816823A8/en not_active IP Right Cessation
- 2008-09-16 NZ NZ584037A patent/NZ584037A/en not_active IP Right Cessation
- 2008-09-16 MX MX2010002927A patent/MX2010002927A/en not_active Application Discontinuation
- 2008-09-16 JP JP2010524891A patent/JP2010539173A/en active Pending
-
2010
- 2010-03-25 CO CO10035469A patent/CO6270205A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209878A1 (en) * | 2002-09-04 | 2004-10-21 | Schering Corporation And Pharmacopeia, Inc. | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20080050384A1 (en) * | 2002-09-04 | 2008-02-28 | Shering Corporation And Pharmacopeia, Inc. | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
WO2008130570A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541587A (en) * | 2010-11-05 | 2013-11-14 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Administration of NEDD8 activating enzyme inhibitor |
WO2015026634A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
Also Published As
Publication number | Publication date |
---|---|
CA2699761A1 (en) | 2009-03-26 |
EP2200584A2 (en) | 2010-06-30 |
MX2010002927A (en) | 2010-06-01 |
JP2010539173A (en) | 2010-12-16 |
KR20100072253A (en) | 2010-06-30 |
WO2009038701A3 (en) | 2009-09-11 |
NZ584037A (en) | 2012-08-31 |
SG184760A1 (en) | 2012-10-30 |
BRPI0816823A8 (en) | 2016-02-10 |
AU2008301925A1 (en) | 2009-03-26 |
CN101854915A (en) | 2010-10-06 |
CO6270205A2 (en) | 2011-04-20 |
BRPI0816823A2 (en) | 2015-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101884960B1 (en) | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors | |
CN101360422B (en) | Oncogenic Ras-specific cytotoxic compound and methods of usethereof | |
AU2016309002A1 (en) | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment | |
AU2927999A (en) | Use of epothilones for the treatment of cancer | |
CN104114168A (en) | Combination therapy (vemrufenib and a MDM2 inhibitor) for the treatment proliferative disorders | |
Morgan et al. | RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid | |
CN104997808A (en) | Method and compositions for treatment of cancer | |
CN105377299A (en) | Combination therapy comprising dihydropyrazino-pyrazine compound and androgen receptor antagonist for treating prostate cancer | |
US20160151406A1 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
WO2022062223A1 (en) | Application of auranofin in preparation of drug for treatment of castration-resistant prostate cancer | |
CN101808636B (en) | Treatment of melanoma | |
JP2021512105A (en) | Combination therapy for the treatment of gastrointestinal stromal tumors | |
US20100286038A1 (en) | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same | |
US20050267140A1 (en) | Method for treating abnormal cell growth | |
Listro et al. | Urea-based anticancer agents. Exploring 100-years of research with an eye to the future | |
WO2009038701A2 (en) | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same | |
TW200426142A (en) | Treatment of incontinence | |
AU2007259224A1 (en) | Use of a P38 kinase inhibitor for treating psychiatric disorders | |
JP2006504721A (en) | Use of Imatinib (Gleevec, STI-571) to inhibit breast cancer resistance protein (BCRP) -mediated resistance to therapeutic agents | |
US9101631B2 (en) | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer | |
WO2021089005A1 (en) | Use of fgfr inhibitor | |
MX2013004924A (en) | Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihy dro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propy l)-malonamide for the treatment of proliferative disorders. | |
Gordi et al. | PII‐57: Regadenoson's pharmacokinetics in subjects with varying degrees of renal function | |
Yue et al. | PII‐59: Population pharmacokinetic analysis of AVP‐923 (30 mg dextromethorphan and 30 mg quinidine) | |
KR20200068643A (en) | Pharmaceutical composition comprising FGFR selective tyrosine kinase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880116604.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08831837 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008301925 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1459/CHENP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010524891 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2699761 Country of ref document: CA Ref document number: 12010500573 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 584037 Country of ref document: NZ Ref document number: MX/A/2010/002927 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10035469 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2008301925 Country of ref document: AU Date of ref document: 20080916 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107008144 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008831837 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12678320 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0816823 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100317 |